Depommier et al. (2019) conducted a randomized, double-blind, placebo-controlled pilot study in overweight and obese insulin-resistant volunteers with the primary endpoint of assessing safety, tolerability, and metabolic indicators (insulin resistance, circulating lipids, visceral adiposity, and body mass) after daily oral supplementation with Akkermansia muciniphila bacteria [232]. The gene discussed is INS; the disease is Insulin resistance.